NCT07174336 2026-04-17
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
Clinical Trials
32 trialsNCT06380751 2026-04-14
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT03820830 2026-04-09
POLAR
ETOP IBCSG Partners Foundation
Phase 3 Active not recruiting
NCT06065748 2026-04-06
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT07492641 2026-03-25
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
BeOne Medicines
Phase 3 Not yet recruiting
NCT06377852 2026-03-18
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
NCT04862663 2026-03-12
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT06760637 2026-03-02
FourLight-3
Pfizer
Phase 3 Recruiting
NCT04546009 2026-02-20
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT02947685 2026-02-12
PATINA
Alliance Foundation Trials, LLC.
Phase 3 Active not recruiting
NCT02513394 2026-02-10
PALLAS
Alliance Foundation Trials, LLC.
Phase 3 Active not recruiting
NCT05501886 2026-02-10
VIKTORIA-1
Celcuity Inc
Phase 3 Active not recruiting
NCT05909397 2026-02-10
VERITAC-3
Pfizer
Phase 3 Active not recruiting
NCT06757634 2026-02-05
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT04964934 2026-01-16
SERENA-6
AstraZeneca
Phase 3 Active not recruiting
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT02297438 2025-10-27
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT04711252 2025-10-14
SERENA-4
AstraZeneca
Phase 3 Active not recruiting
NCT03425838 2025-09-19
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Borstkanker Onderzoek Groep
Phase 3 Active not recruiting
NCT04478266 2025-09-11
AMEERA-5
Sanofi
Phase 3 Terminated
NCT07061717 2025-07-11
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Not yet recruiting
NCT05207709 2025-04-29
HARMONIA
SOLTI Breast Cancer Research Group
Phase 3 Active not recruiting
NCT01740427 2024-11-14
PALOMA-2
Pfizer
Phase 3 Completed
NCT02028507 2024-09-25
PEARL
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT01942135 2024-04-04
PALOMA-3
Pfizer
Phase 3 Completed
NCT03423199 2024-03-22
PATHWAY
National Cancer Center, Japan
Phase 3 Unknown
NCT01864746 2023-12-12
PENELOPE-B
GBG Forschungs GmbH
Phase 3 Completed
NCT03447132 2023-03-10
SAFIA
International Cancer Research Group, United Arab Emirates
Phase 3 Completed
NCT03969121 2023-03-10
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Kyoto Breast Cancer Research Network
Phase 3 Completed
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT02600923 2022-01-20
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
Pfizer
Phase 3 Completed
NCT04047758 2021-07-20
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer
Shengjing Hospital
Phase 3 Unknown